For example, in models of pancreatic cancer, we discovered that HMGA1 activates pathways downstream of the fibroblast growth factor, FGF19, and inhibitors of FGF19 and its receptor (FGFR4) are already available in the clinic [52]. This evidence concerns the gene FGF19 and pancreatic neoplasm.